The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:86-87 January 4, 2007 Number 1
NextNext

Immunotherapy with a Ragweed Vaccine

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Creticos, P. S.
-PubMed Citation
To the Editor: Creticos et al. (Oct. 5 issue)1 describe the results of a study comparing a vaccine — consisting of an immunostimulatory DNA sequence conjugated to Amb a 1, a ragweed-pollen antigen — with saline placebo. The study showed improvement of several end points of nasal allergen challenge in the group receiving the Amb a 1–immunostimulatory oligodeoxyribonucleotide conjugate (AIC) vaccine, as compared with the placebo group. However, we question whether saline is the appropriate comparative agent.

Standardized allergen extracts are known to be effective as immunotherapy for allergic diseases. Dynavax Technologies is developing an inhaled immunostimulatory sequence without a . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.